Induction of potent antitumor immunity by in situ targeting of intratumoral DCs
J. Clin. Invest. Katsuyoshi Furumoto, et al. 113:774 doi:10.1172/JCI19762 [Go to this article.]

Figure 5
CpG restores the capacity of B16 tumoral DCs to process tumor Ag’s and prime tumor Ag-specific CD8 T cells. Mice were inoculated with B16 parental, B16-CCL20, or B16-mock–transduced tumor cells followed by intratumoral injections of CpG or ODN-CTR. (A) Fifteen days later the percentage of I-Ab⁺ CD11c⁺ DCs present in the tumors was analyzed. (B) Dot plot shows the expression of CD86 on I-Ab⁺ CD11c⁺ gated DCs. CD86 mean fluorescence intensity (MFI) is shown in parentheses above each quadrant. One representative experiment out of three is shown. (C) Graphs show CD86 MFI on gated tumoral DCs and DCs in tumor-draining LNs. Results shown are the mean of three separate experiments. (D–F) Graded numbers of purified CD11c⁺ tumoral DCs were cultured in the presence of 3 × 10⁵ purified allogeneic BALB/c T cells (D) or 3 × 10⁵ purified CD8 OVA_257-264–TCR transgenic T cells (E), and T cell proliferation was measured 5 days later. Purified CD11c⁺ tumoral DCs were cultured in the presence of 5 × 10⁴ OVA_257-264–specific CD8 T cells (clone B3Z), and IL-2 secretion was measured by ELISA 24 hours later (F). Results shown are representative of two separate experiments. *P < 0.05 between CpG-injected groups and group controls.